Chroma bags 135M to bolster epigenetic-focused platform - FierceBiotech
| X2S Stock | EUR 2.64 0.04 1.54% |
Roughly 55% of Sinopharm Group's stockholders are presently thinking to get in. The analysis of current outlook of investing in Sinopharm Group Co suggests that some traders are interested regarding Sinopharm Group's prospects. The current market sentiment, together with Sinopharm Group's historical and current headlines, can help investors time the market. In addition, many technical investors use Sinopharm Group stock news signals to limit their universe of possible portfolio assets.
Sinopharm Group stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Sinopharm daily returns and investor perception about the current price of Sinopharm Group Co as well as its diversification or hedging effects on your existing portfolios.
Sinopharm |
Chroma bags 135M to bolster epigenetic-focused platform FierceBiotech
Read at news.google.com
 |
Sinopharm Group Fundamental Analysis
We analyze Sinopharm Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinopharm Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinopharm Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Sinopharm Group is rated below average in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Sinopharm Group Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sinopharm Group stock to make a market-neutral strategy. Peer analysis of Sinopharm Group could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics with similar companies.
Peers
Sinopharm Group Related Equities
| X2S1 | SINOPHARM GROUP | 1.55 | ||||
| X2S | Sinopharm Group | 1.54 | ||||
| CLH | Cardinal Health | 0.94 | ||||
| 59Z | MEDIPAL HOLDINGS | 0.70 | ||||
| ABG | AmerisourceBergen | 0.37 | ||||
| S1R | Shanghai Pharmaceuticals | 0.63 | ||||
| PBV | Prestige Consumer | 0.66 | ||||
| PD2 | Patterson Companies | 1.34 | ||||
| HS2 | Henry Schein | 2.60 |
Complementary Tools for Sinopharm Stock analysis
When running Sinopharm Group's price analysis, check to measure Sinopharm Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinopharm Group is operating at the current time. Most of Sinopharm Group's value examination focuses on studying past and present price action to predict the probability of Sinopharm Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinopharm Group's price. Additionally, you may evaluate how the addition of Sinopharm Group to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |